aripiprazole (Q411188)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

chemical compound

OPC 14597
OPC-14597
OPC 31

Language	Label	Description	Also known as
English	aripiprazole	chemical compound	OPC 14597 OPC-14597 OPC 31

Statements

type of chemical entity

0 references

heterocyclic compound

0 references

0 references

chemical structure

Aripiprazole.svg
512 × 499; 6 KB

1 reference

imported from Wikimedia project

German Wikipedia

447.148032 dalton

1 reference

language of work or name

Aripiprazole (English)

3 October 2016

chemical formula

C₂₃H₂₇Cl₂N₃O₂

1 reference

language of work or name

Aripiprazole (English)

19 November 2016

canonical SMILES

C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

1 reference

language of work or name

Aripiprazole (English)

19 November 2016

defined daily dose

15 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05AX12

15 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05AX12

13.3 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05AX12

active ingredient in

Abilify Maintena

1 reference

European Medicines Agency product number

EMEA/H/C/002755

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002755/human_med_001711.jsp

22 March 2017

1 reference

14 February 2018

Aripiprazole Accord

1 reference

European Medicines Agency product number

EMEA/H/C/004021

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004021/human_med_001920.jsp

22 March 2017

Aripiprazole Mylan Pharma

1 reference

European Medicines Agency product number

EMEA/H/C/003803

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003803/human_med_001867.jsp

22 March 2017

Aripiprazole Sandoz

1 reference

European Medicines Agency product number

EMEA/H/C/004008

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004008/human_med_001892.jsp

22 March 2017

Aripiprazole Zentiva

1 reference

European Medicines Agency product number

EMEA/H/C/003899

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003899/human_med_001868.jsp

22 March 2017

World Health Organisation international non-proprietary name

aripiprazole (English)

1 reference

language of work or name

aripiprazole (English)

3 October 2016

medical condition treated

1 reference

language of work or name

13 December 2016

Tourette syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

personality disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Alzheimer's disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

mental disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

obsessive-compulsive disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

post-traumatic stress disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

borderline personality disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

schizoaffective disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(R,R)-asenapine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(R,R)-asenapine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

cognitive disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 1A

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

5-hydroxytryptamine receptor 1B

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

5-hydroxytryptamine receptor 1D

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

5-hydroxytryptamine receptor 2A

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

5-hydroxytryptamine receptor 2C

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

dopamine receptor D2

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Histamine receptor H1

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

legal status (medicine)

applies to jurisdiction

United States of America

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category B3

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Aripiprazole

20 July 2017

subject has role

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

atypical antipsychotic

0 references

ARIPiprazole

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

0 references

0 references

Commons category

Aripiprazole

0 references

Identifiers

subject named as

aripiprazol

0 references

InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

1 reference

language of work or name

Aripiprazole (English)

19 November 2016

CEUORZQYGODEFX-UHFFFAOYSA-N

2 references

language of work or name

Aripiprazole (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

aripiprazole (English)

19 November 2016

CEUORZQYGODEFX-UHFFFAOYSA-N

CAS Common Chemistry

10 April 2021

https://commonchemistry.cas.org/detail?cas_rn=129722-12-9

1 reference

language of work or name

Aripiprazole (English)

19 November 2016

2 references

language of work or name

Aripiprazole (English)

19 November 2016

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

mapping relation type

2 references

language of work or name

ARIPIPRAZOLE (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

1 reference

language of work or name

ARIPIPRAZOLE (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

UniChem compound ID

1 reference

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

ARIPIPRAZOLE (English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one (English)

CAS no.: 129722-12-9 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one (English)

CAS no.: 129722-12-9 (English)

1 reference

language of work or name

Aripiprazole (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

aripiprazole (English)

19 November 2016

MeSH descriptor ID

subject named as

Aripiprazole

0 references

MeSH concept ID

0 references

D03.383.606.170

0 references

D03.633.100.810.835.122

0 references

1 reference

Global Substance Registration System

language of work or name

aripiprazole (English)

19 November 2016

1 reference

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

aripiprazole (English)

19 November 2016

matched by identifier from

CEUORZQYGODEFX-UHFFFAOYSA-N

MedlinePlus drug identifier

route of administration

oral administration

0 references

route of administration

intramuscular injection

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

aripiprazole (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

aripiprazole (English)

3 October 2016

1 reference

language of work or name

aripiprazole (English)

3 October 2016

0 references

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

UK Parliament thesaurus ID

subject named as

Aripiprazole

0 references

1 reference

Global Substance Registration System

language of work or name

aripiprazole (English)

19 November 2016

1 reference

based on heuristic

inferred by common MeSH mappings on source and on Wikidata

25 May 2023

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(32 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Aripiprazole

Retrieved from "https://www.wikidata.org/w/index.php?title=Q411188&oldid=2186706692"